| Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. | |
| | |
MedLine Citation:
|
PMID: 19926121 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To compare the diagnostic accuracy of positron emission tomography/computed tomography (PET/CT), pelvic Doppler ultrasonography (US), abdomino-pelvic computed tomography (CT), and pelvic magnetic resonance imaging (MRI) for detection of ovarian cancer and to assess the role of PET/CT in evaluating the dissemination of ovarian cancer. PATIENTS AND METHODS: One hundred thirty-three women suspected to have ovarian cancer were enrolled in a prospective study before surgery between March 2005 and August 2007. The accuracy of each modality in detection of malignancy was estimated by computing the relevant areas under a receiver operating characteristics curve. Histopathologic results served as the reference standard. RESULTS: Histopathology showed benign tumors in 25 patients, borderline tumors in 13 patients, and malignant tumors in 95 patients. In distinguishing malignant/borderline from benign ovarian tumors, the accuracy of PET/CT (0.921) was higher than that of pelvis US (0.830) and abdomino-pelvic CT or pelvis MRI (0.749; P=0.013). Radiologic staging by PET/CT was concordant with surgical staging in 78% of patient and PET/CT revealed 15 (15.8%) unpredicted extra-abdominal lymph node metastasis in 95 patients with ovarian cancer. In addition, PET/CT detected new, unexpected co-existing malignant tumors in five (3.8%) cases including two thyroid tumors, two breast tumors, and one pancreatic neuroendocrine cancer. CONCLUSION: PET/CT is superior to pelvis US, abdomino-pelvic CT, and pelvic MRI for diagnosis of malignant ovarian tumors and is useful in revealing metastatic ovarian cancer and co-existing malignant tumors. Therefore, we suggest that PET/CT could be used during pre-operative evaluation of patients suspected to have ovarian cancer. |
| | |
Authors:
|
Eun Ji Nam; Mi Jin Yun; Young Taik Oh; Jae Wook Kim; Jae Hoon Kim; Sunghoon Kim; Yong Wook Jung; Sang Wun Kim; Young Tae Kim |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't Date: 2009-11-18 |
Journal Detail:
|
Title: Gynecologic oncology Volume: 116 ISSN: 1095-6859 ISO Abbreviation: Gynecol. Oncol. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-15 Completed Date: 2010-03-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0365304 Medline TA: Gynecol Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 389-94 Citation Subset: IM |
Affiliation:
|
Women's Cancer Clinic, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Female Fluorodeoxyglucose F18 / diagnostic use Humans Magnetic Resonance Imaging Middle Aged Neoplasm Staging Ovarian Neoplasms / diagnosis*, pathology, radionuclide imaging, ultrasonography Positron-Emission Tomography ROC Curve Radiopharmaceuticals / diagnostic use Tomography, X-Ray Computed Ultrasonography, Doppler Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Receptor Activator for Nuclear Factor kappa B Ligand (RANKL) as an osteoimmune key regulator in bone...
Next Document: Influence of TEGDMA on the mammalian cell cycle in comparison with chemotherapeutic agents.